The Need

The need for effective vaccine development platforms has never been more pressing, especially in the face of evolving pathogens such as the measles virus. Current vaccine production methods often face challenges in achieving optimal expression levels and immunogenicity, hindering their efficacy. There is a crucial demand for a streamlined approach that can swiftly generate vaccine candidates with enhanced expression and immunogenic properties.

The Technology

Our Measles Platform for Generation of Vaccine Candidates offers a revolutionary solution to the challenges encountered in traditional vaccine development. By leveraging the highly conserved gene junction between the P and M genes of the measles virus genome, we have optimized a specific location for the insertion of foreign genes. This strategic insertion ensures maximal expression while maintaining viral viability. Furthermore, our technology incorporates antigen modification techniques, including codon optimization and structural modifications, to enhance immunogenicity and antigen stability.

Commercial Applications

• Rapid development of vaccine candidates against emerging pathogens such as SARS-CoV-2 variants.
• Customized vaccine development for specific target antigens, facilitating personalized medicine initiatives.
• Production of multivalent vaccines targeting multiple pathogens simultaneously, improving vaccination coverage and efficacy in diverse populations.

Benefits/Advantages

• Enhanced expression levels of foreign antigens, leading to improved vaccine efficacy.
• Tailored modifications ensure optimal immunogenicity and antigen stability, maximizing vaccine potency.
• Streamlined vaccine development process accelerates time-to-market and reduces production costs.
• Versatility in accommodating various antigens and pathogens enables broad application across infectious disease research and vaccine development efforts.
• Compatibility with existing vaccine manufacturing infrastructure allows for seamless integration into pharmaceutical production pipelines.